Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07005128 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
A Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT07005128 is a Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 330 participants, above the 228-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT07005128, a Phase 3 study of Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Durvalumab
- DRUG Tarlatamab
Study Locations (20)
California
- University of California Los Angeles - Santa Monica
- Presbyterian Intercommunity Hospital Health Whitter Hospital - Whittier
Minnesota
- Allina Health System dba Allina Health Cancer Institute - Minneapolis
- Mayo Clinic - Rochester
Tennessee
- Baptist Cancer Center - Memphis
- United States Oncology Regulatory Affairs Corporate Office - Nashville
Texas
- US Oncology Research Investigational Products Center - Irving
- Texas Oncology Northeast Texas - Tyler
Buenos Aires
- Cemic - Ciudad Autonoma de Buenos Aires
- Hospital Universitario Austral - Pilar
Arkansas
- Saint Bernards Medical Center - Jonesboro
Connecticut
- Yale New Haven Hospital - New Haven
Illinois
- University of Illinois Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2029-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07005128
The ClinicalTrials.gov registry entry for NCT07005128 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 228-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (45% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT07005128 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07005128 about?
NCT07005128 is a clinical study titled "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)". The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
What is the current status of trial NCT07005128?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2025-08-18. Estimated completion is 2029-07-15.
What conditions does trial NCT07005128 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT07005128?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Durvalumab (DRUG), Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT07005128?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07005128 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Small-cell Lung Cancer
All registered trials for this condition
Extensive-stage Small-cell Lung Cancer
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.